IOP-lowering

Studying aqueous humour outflow with aqueous angiographyA pioneering dye-based technique that enables aqueous humour outflow to be studied has the potential to improve glaucoma angle-based procedures and surgery outcomes.
Sustained-release topical rings promising for glaucomaA single bimatoprost topical ring has been shown to be effective and safe for lowering IOP over six months, according to results from a phase II study.
Bimatoprost sustained-release implants: Potential new pathway for glaucoma patientsThe bimatoprost sustained-release implant (bimatoprost SR, Allergan) improves compliance for patients with problematic compliance with topical IOP-lowering glaucoma drugs and controlled the IOP for 6 months after injection.
Long-term implant showing potential in glaucoma therapyAn extended-release therapy that encapsulates travoprost in an intracameral implant showed a statistically significant and clinically meaningful reduction in IOP with results comparable to topical once-daily travoprost ophthalmic solution, said Tom R. Walters, MD, Texan Eye, Austin.
Ocular insert overcoming glaucoma treatment challengesA bimatoprost-releasing ocular insert that rests in the conjunctival fornix (ForSight VISION5) lowered IOP in patients with ocular hypertension or glaucoma by an average of 4 to 6 mm Hg from baseline over 6 months.
The who, what, when, why and how of selective laser trabeculoplastySelective laser trabeculoplasty is safe and effective for reducing IOP in patients with glaucoma. However, not all patients respond to treatment and its effects are not permanent even in those who respond well.
Novel modalities expand glaucoma therapeutic arsenalActive research in neuroprotection, neuroregeneration, and sustained drug delivery is expected to lead to better options for management of glaucoma.
Filtration device lowers IOP in patients with PEG and POAGA glaucoma filtration device was equally effective in reducing IOP in pseudoexfoliative glaucoma and primary open-angle glaucoma patients, in a recent small study.
Positive results for Aerie glaucoma therapy studyAerie Pharmaceuticals has reported successful results for a phase IIb trial for its IOP-lowering therapy—once-daily, quadruple-action Roclatan, a combination of Aerie’s triple-action Rhopressa with latanoprost.